rs185392267 — PCSK9 Arg96Cys

PCSK9 Arg96Cys — A Rare Gain-of-Function Variant Driving Familial Hypercholesterolemia

The PCSK9 protein acts as a master regulator of LDL receptors¹¹ LDL receptors
low-density lipoprotein receptors on the liver surface that clear LDL-cholesterol from the bloodstream. When PCSK9 binds to an LDL receptor, it hijacks the receptor into a lysosomal degradation pathway instead of allowing it to recycle back to the cell surface. Fewer receptors means less LDL clearance, and plasma LDL-cholesterol climbs. The rs185392267 T allele — encoding Arg96Cys²² Arg96Cys
arginine-to-cysteine substitution at amino acid position 96, in the propeptide domain of PCSK9 — is a gain-of-function (GOF) variant that amplifies this degradation activity beyond the normal range, causing autosomal dominant hypercholesterolemia³³ autosomal dominant hypercholesterolemia
a hereditary condition where a single copy of the mutant gene is sufficient to cause significantly elevated LDL-cholesterol.

The Mechanism

Wild-type PCSK9 degrades LDL receptors through two routes: an intracellular pathway, where newly synthesized PCSK9 binds LDLR in the trans-Golgi network and routes it directly to lysosomes; and an extracellular pathway, where secreted PCSK9 binds the EGF-A domain⁴⁴ EGF-A domain
epidermal growth factor-like repeat A domain, the LDLR segment that recognizes LDL at the cell surface and prevents recycling after endocytosis.

The Arg96Cys substitution introduces a cysteine residue into the propeptide/inhibitor domain of PCSK9. Cell-based studies by Elbitar et al. (2018)⁵⁵ Cell-based studies by Elbitar et al. (2018)
New Sequencing Technologies Help Revealing Unexpected Mutations in Autosomal Dominant Hypercholesterolemia. Scientific Reports 2018 demonstrated that PCSK9-R96C accumulates at higher cellular levels (~60% more total protein than wild-type) but is secreted at a reduced rate (~60% less secretion). Despite reduced secretion, when expressed in HepG2 hepatocyte cells, PCSK9-R96C degrades the LDL receptor to a greater extent than wild-type PCSK9 via the intracellular pathway. The net effect: more LDLR destruction, fewer surface receptors, and less hepatic LDL clearance — driving chronically elevated plasma LDL-C.

The Evidence

Elbitar et al. identified PCSK9-R96C⁶⁶ Elbitar et al. identified PCSK9-R96C in a French patient carrying a compound heterozygous state alongside a pathogenic APOB variant — the first such combination reported. The patient had severe hypercholesterolemia consistent with an additive effect. Importantly, the paper demonstrated that PCSK9-R96C is a genuine GOF mutation capable on its own of causing autosomal dominant hypercholesterolemia. An earlier cohort study reported R96C in three Danish familial hypercholesterolemia patients with mean untreated total cholesterol of 271.5 ± 46.0 mg/dL and LDL-C of 191.4 ± 34.4 mg/dL, with 2 of 3 patients presenting coronary artery disease.

ClinVar variation 440714 classifies c.286C>T as "conflicting interpretations of pathogenicity": 2 pathogenic, 1 likely pathogenic, and 6 uncertain significance submissions — a reflection of the variant's rarity rather than contradictory functional evidence. The functional cell studies constitute strong mechanistic evidence for pathogenicity.

For PCSK9 GOF mutations as a class, Hopkins et al. (2015)⁷⁷ Hopkins et al. (2015) found that heterozygous carriers treated with alirocumab⁸⁸ alirocumab
anti-PCSK9 monoclonal antibody; brand name Praluent achieved 62.5–73% LDL-C reductions. This is mechanistically expected: PCSK9 inhibitors prevent PCSK9 from binding LDLR regardless of whether the PCSK9 carries a GOF mutation, restoring receptor recycling.

Practical Actions

Carriers of Arg96Cys should treat their lipid profile as pharmacologically actionable. First-line therapy is high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg), which reduces hepatic cholesterol synthesis, upregulates LDLR expression, and typically lowers LDL-C by 50–60%. Because statin therapy also transcriptionally upregulates PCSK9 expression, the GOF variant partially blunts statin response compared with LDLR-deficient FH. Adding ezetimibe (10 mg daily) blocks intestinal cholesterol reabsorption and achieves an additional 15–20% LDL-C reduction. If LDL-C remains above the target (<70 mg/dL for high cardiovascular risk; <55 mg/dL for very high risk per 2025 ESC/EAS focused update), a PCSK9 inhibitor (evolocumab or alirocumab) is the next step and is particularly rational here: it directly counteracts the variant's mechanism. Combined statin + ezetimibe + PCSK9 inhibitor can lower LDL-C by 75–80% from baseline. Regular lipid panels, lipoprotein(a) measurement, and cardiovascular imaging (coronary artery calcium score) help stratify individual risk.

Interactions

The Arg96Cys variant is found in the same gene as the well-studied PCSK9 loss-of-function variants rs11591147 (R46L) and rs562556 (E670G), which have the opposite effect — reducing LDLR degradation and lowering LDL-C. A compound heterozygote inheriting one R96C GOF allele alongside a PCSK9 LOF allele in the other copy may have partially attenuated disease severity, though no case is reported. Notably, the Elbitar paper identified the first compound heterozygote combining PCSK9-R96C with an APOB pathogenic variant (rs121918386 class), in whom the additive lipid phenotype was severe — an important clinical scenario where standard FH genetic panels may underestimate disease burden if only one gene is sequenced.